Information Provided By: 
Fly News Breaks for December 2, 2016
LLY
Dec 2, 2016 | 14:48 EDT
Evercore ISI analyst John Scotti said the FDA approval of Jardiance's sNDA for the reduction of CV mortality allows Eli Lilly's salesforce to directly promote the CV death indication, which he believes bodes well for the growth of the Jardiance franchise. The company, which has maintained that updates to the label and treatment guidelines expected in 2017 are likely to cause an inflection in the drug's sales, said the updated label should be on-line by next week, added Scotti, who has a Hold rating on Lilly shares.
News For LLY From the Last 2 Days
There are no results for your query LLY
